ATE361368T1 - Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion - Google Patents

Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion

Info

Publication number
ATE361368T1
ATE361368T1 AT98942413T AT98942413T ATE361368T1 AT E361368 T1 ATE361368 T1 AT E361368T1 AT 98942413 T AT98942413 T AT 98942413T AT 98942413 T AT98942413 T AT 98942413T AT E361368 T1 ATE361368 T1 AT E361368T1
Authority
AT
Austria
Prior art keywords
vector
protein
host
alphavirus
rsv
Prior art date
Application number
AT98942413T
Other languages
English (en)
Inventor
Mark Parrington
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of ATE361368T1 publication Critical patent/ATE361368T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98942413T 1997-09-04 1998-09-03 Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion ATE361368T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/923,558 US6060308A (en) 1997-09-04 1997-09-04 RNA respiratory syncytial virus vaccines

Publications (1)

Publication Number Publication Date
ATE361368T1 true ATE361368T1 (de) 2007-05-15

Family

ID=25448878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98942413T ATE361368T1 (de) 1997-09-04 1998-09-03 Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion

Country Status (9)

Country Link
US (2) US6060308A (de)
EP (1) EP1009846B1 (de)
JP (1) JP2001514857A (de)
AT (1) ATE361368T1 (de)
AU (1) AU742046B2 (de)
BR (1) BR9815642B1 (de)
CA (1) CA2301891C (de)
DE (1) DE69837708T2 (de)
WO (1) WO1999011808A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
US7465574B2 (en) * 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
US6830748B1 (en) * 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
EP1707633A1 (de) * 1997-11-14 2006-10-04 Sanofi Pasteur Limited Alphavirus-Vektoren als Impfstoffe gegen Paramyxovirus
CA2309826A1 (en) * 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
KR100481879B1 (ko) * 2001-02-08 2005-04-11 크레아젠 주식회사 (+)-단일쇄 ｒｎａ 재조합 벡터내 삽입 서열의 유전적 안정성을 증가시키는 방법
EP2848692B1 (de) 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Alphavirus-Vektoren für Influenzavirus-Impfstoffe
AU2009236585B2 (en) * 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
JP6046348B2 (ja) * 2008-11-18 2016-12-14 タケダ ヴァクシーンズ， インコーポレイテッド Ｒｓｖｆｖｌｐならびにその製造および使用の方法
HUE028085T2 (en) * 2009-06-24 2016-11-28 Glaxosmithkline Biologicals Sa Recombinant RSV antigens
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
EP2591114B1 (de) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisierung grosser säugetiere durch niedrige dosen von rna
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
MX342608B (es) 2010-07-06 2016-10-06 Novartis Ag * Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
RU2013154295A (ru) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
EP2729165B1 (de) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
KR102806300B1 (ko) * 2023-01-13 2025-05-14 클립스비엔씨 주식회사 호흡기 신시치아 바이러스 변이체를 포함하는 호흡기 신시치아 바이러스 백신용 융합단백질 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE105334T1 (de) 1988-04-22 1994-05-15 Upjohn Co Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
AU4594996A (en) * 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5614372A (en) * 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines

Also Published As

Publication number Publication date
US6428324B1 (en) 2002-08-06
EP1009846B1 (de) 2007-05-02
US6060308A (en) 2000-05-09
JP2001514857A (ja) 2001-09-18
CA2301891A1 (en) 1999-03-11
CA2301891C (en) 2010-01-19
DE69837708T2 (de) 2008-01-10
BR9815642B1 (pt) 2013-09-17
AU742046B2 (en) 2001-12-13
BR9815642A (pt) 2002-12-31
DE69837708D1 (de) 2007-06-14
AU9056998A (en) 1999-03-22
EP1009846A1 (de) 2000-06-21
WO1999011808A1 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
ATE361368T1 (de) Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion
Smerdou et al. Two-helper RNA system for production of recombinant Semliki forest virus particles
DK0724642T3 (da) Nukleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
CY1116837T1 (el) Αλληλουχιες κυκλοϊου σχετικου με την νοσο απισχνασης του χοιριδιου (map)
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
SE9003978D0 (sv) Dna expressionssystem baserade paa ett virus replikon
DE69935714D1 (de) Anti-virale vektoren
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
Karasev et al. Screening of the closterovirus genome by degenerate primer-mediated polymerase chain reaction
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
NO20076452L (no) cDNA construct of Salmonidae alphavirus
BR9508645A (pt) Vacina da peritonite infecciosa felina
US20160228531A1 (en) Treatment of hepatitis d virus infections by redirection of t cells
ES2367245T8 (es) Virus recombinante que expresa adn foráneo que codifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo.
EP0789563A4 (de) Impfstoffe gegen den hepatitisvirus
ATE414905T1 (de) Diabetesmodell
PT1254663E (pt) Agente antiviral
ATE476511T1 (de) Nukleinsäuren von hdv, deren bruchstücken und deren verwendungen
ATE474927T1 (de) Schützende hochmolekulargewichtsproteine aus haemophilus influenzae
CA2086577A1 (en) Potential target for immunotherapy to prevent replication of hiv (aids virus) in humans: cdna and protein for a putative regulator of hiv gag polyprotein expression reconstructed from the antisense strand of human p53 gene
HE et al. Cloning, expression and identification of SARS-CoV S1 gene in yeast p. methanolica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties